News and Trends 10 Feb 2018 Superbugs: Fighting Antibiotic Resistance at the Science Museum An exhibition at the Science Museum London features some of the deadliest superbugs on Earth and the stories of the people fighting against the threat of antibiotic resistance. It is estimated that, by 2050, 10 million people will die every year due to infections with antibiotic-resistant bacteria. Meaning that the numbers will be higher than […] February 10, 2018 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 8 Feb 2018 GSK’s Company Starts Phase III Trials with Two-Drug HIV Treatment ViiV Healthcare has just started a clinical trial to test if its two-drug regimen for HIV can work as well as current three-drug HIV treatment. Most antiretroviral treatments used to keep HIV at bay employ a combination of three different drugs, exposing patients to the long-term toxicity of three different compounds at once. London-based ViiV […] February 8, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 7 Feb 2018 Scottish CAR-T Biotech Adds Another Stellar Partner to Its Roster TC Biopharm has signed a new pharma partner, the Japan-based NIPRO Corporation, who will give the biotech a leg up in the CAR-T game. Hot on the heels of the two huge CAR-T acquisitions of Juno and Kite, Japanese pharma NIPRO Corporation is planting a foot in the game by partnering with Scotland-based TC Biopharm […] February 7, 2018 - 1 minutemin - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 6 Feb 2018 Spring Cleaning: AstraZeneca Ditches Underperforming Asthma and Cancer Candidates AstraZeneca has given up on the development of its PD-1 checkpoint inhibitor drug, which was the headline act when its subsidiary MedImmune acquired Amplimmune in 2013. There was no sentiment as pharma giant AstraZeneca cut a number of drugs from its pipeline after they did not perform as expected during clinical trials. The biggest name to get […] February 6, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 5 Feb 2018 New Antiviral for RSV Lung Infections Shows Promise in Phase IIa ReViral’s candidate RV521 showed its potential for the treatment of respiratory syncytial virus (RSV) infections by reducing viral load and mucus levels. London-based biotech ReViral discovers and develops antiviral drugs, focusing particularly on the treatment of diseases caused by the respiratory syncytial virus (RSV). The biotech’s candidate, RV521, has undergone a Phase IIa clinical trial during […] February 5, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
More News! 5 Feb 2018 A DNA-Based Diagnostic Company Rakes in £1.8M to Combat Antimicrobial Resistance A new molecular diagnostics company, LIG Biowise, has just closed a £1.8M Series A fundraising round in its effort to combat antimicrobial resistance. Based in Manchester, LIG Biowise, is working on a DNA-based diagnostic to catch antibiotic resistant infections early. The company has now closed a Series A of £1.8M (€2.0M), led by Hong Kong-based Phoenix Bridge, to fund […] February 5, 2018 - 1 minutemin - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 31 Jan 2018 Your Pee Could Be Used to Build an Artificial Adrenal Gland Scientists have started generating artificial glands using cells derived from urine, which will allow the study of adrenal disorders that affect growth, development, and metabolism. Researchers at Queen Mary University of London have used cells in urine to begin generating an artificial adrenal gland that could be used to treat adrenal gland disorders. The study, published in Cell Reports, […] January 31, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 31 Jan 2018 Gene Synthesizing Biotech Gets $12M to Boost the Synbio Field Evonetix has closed a Series A fundraising round to support the development of its gene synthesis platform, an important tool in the emerging synbio field. Evonetix, based in Cambridge, UK, is developing a scalable, high fidelity gene synthesis approach that could be a key tool in the growing synbio field. The biotech has closed a […] January 31, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 30 Jan 2018 Update: Pocket Device makes its Debut in Whole Human Genome Sequencing Update (30/01/2018): Oxford Nanopore has published a study in Nature Biotechnology outlining the first use of its pocket MinION device to sequence a human genome. The device was able to read sequences of DNA that are “hundreds of times larger than usual,” helping scientists better reconstruct the whole genome sequence. MinION costs less than $1,000 and […] January 30, 2018 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 29 Jan 2018 London Tops Europe for Life Sciences Investment in 2017 Investment in London’s life sciences companies reached almost £1B in 2017, beating the likes of Berlin and Paris to top spot. A new study has found that London’s life sciences industry received the most investment out of any city in Europe in 2017. Over the last 5 years, companies in the capital have raised £2.8Bn (€3.2Bn), with £909M […] January 29, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 26 Jan 2018 New British Spinout May Get Snapped Up by Allergan for $400M KaNDy Therapeutics, a women’s health spinout helmed by Mary Kerr, is rumored to be in acquisition talks that value the company at $400M (€322M). Details are sparse, but according to a report from Bloomberg, Stevenage-based KaNDy Therapeutics is supposedly in the late stages of a discussion with Allergan about a possible buyout. KaNDy, a recent spinout […] January 26, 2018 - 1 minutemin - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 25 Jan 2018 Yet More Good News for GW Pharma’s Cannabinoid Drug Against Epilepsy New data in The Lancet provides further support for GW Pharma’s drug, Epidiolex, for the treatment of a rare form of epilepsy. GW Pharmaceuticals has achieved encouraging Phase III results for Epidiolex, which have been published in leading scientific journal, The Lancet. The company’s lead candidate is being developed for the treatment of epilepsy – a […] January 25, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email